Search Medical Condition
Please enter condition
Please choose location
 

Batumi, Georgia Clinical Trials

A listing of Batumi, Georgia clinical trials actively recruiting patients volunteers.

RESULTS

Found (5) clinical trials

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect)-controlled, event-driven, multicenter study in patients who are hospitalized ...

Phase

0.0 miles

Learn More »

Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

This trial is designed to determine what effects the human body has on the investigational medicine, ABP 798, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, rituximab, in patients ...

Phase

0.0 miles

Learn More »

Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer

The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer

Phase

0.0 miles

Learn More »

Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia

Lefamulin is a potent, semi-synthetic antibacterial belonging to a novel class known as the pleuromutilins. The oral dosage form of lefamulin is under investigation in this study. Lefamulin's in vitro antibacterial profile includes the most important bacterial pathogens causing respiratory tract infection (RTI). The antibacterial spectrum comprises S. pneumoniae, H. ...

Phase

0.0 miles

Learn More »

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children Known or Suspected to be Caused by Susceptible Gram-positive Organisms Including MRSA

To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged 3 months to 17 years, known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.

Phase

2.3 miles

Learn More »